Peanut allergy immunotherapy - DBV Technologies

Drug Profile

Peanut allergy immunotherapy - DBV Technologies

Alternative Names: DBV 712; EPIT® Peanut; Viaskin Peanut

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator DBV Technologies
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Peanut hypersensitivity
  • New Molecular Entity No

Highest Development Phases

  • Phase III Peanut hypersensitivity

Most Recent Events

  • 05 Jan 2017 DBV Technologies plans the follow-up phase III PEOPLE trial for Peanut hypersensitivity (In children) in USA, Canada, Ireland, Germany and Australia (Topical) (NCT03013517)
  • 01 Sep 2016 DBV Technologies completes a phase II trial in Peanut hypersensitivity in USA, Canada, France and the Netherlands (NCT01955109)
  • 01 Aug 2016 DBV Technologies plans phase III REALISE study in Peanut hypersensitivity in North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top